08 March 2012: ModiQuest, Nijmegen, The Netherlands: Jos Raats, CEO of ModiQuest has been invited to UCB, England on March 8th to give a seminar on their novel, effective antibody-based treatments for Rheumatoid Arthritis.

Pharma-Biotech Collaboration

Big Pharma Turning to Bio-generics: the next big thing in 2012

By Jos Raats, CEO ModiQuest Research

1. Think about what the antibody has to do

Monoclonal antibodies are useful tools for both medical treatment, diagnostics as well as research. Taking this into account, the application will define the specification and critical parameters. These issues can be dealt with during the process of antibody generation, optimisation and production in a QBD (Quality By Design) approach using a combination of currently available (recombinant) antibody technologies.

2. Determine the limiting factor for your specific approach

3. Finally, find the right service provider that can integrate and coordinate all your requirements to generate the required antibody molecule

By Jos Raats, CEO ModiQuest Research

A total of sixteen companies entered into the annual competition, which provides 5000 Euro and a work of art as the prize.

CEO, Jos Raats commented “We’re proud to be the Mercator award winner this year, which is a testament to the hard work of the superb team we have here, and the fact that we’re delivering a great antibody service that’s meeting the needs of our world-wide pharmaceutical and biotechnology clients. ”

For more information, contact Jos Raats at info@modiquestresearch.com.

ModiQuest Research Delivers Novel Rheumatoid Arthritis Therapeutic Antibodies

30 November 2011: ModiQuest Research, Nijmegen, The Netherlands: ModiQuest Research, the full service provider for antibody generation, engineering and optimization, has successfully generated novel antibody therapeutic leads and diagnostics for rheumatoid arthritis (RA). Using its extensive antibody generation technology platform, which includes phage display and high throughput mouse hybridoma generation, the company identified specific anti-citrulline antibodies that demonstrate high efficacy levels in preclinical RA models.

The company has been especially successful in supporting a variety of autoimmune disease projects in addition to rheumatoid arthritis, including multiple sclerosis, and lupus erythematosus. By using a combination of a unique technology service platform and a growing collection of immunological reagents for autoimmune disease research, ModiQuest provides the antibody expertise, as well as customised antigens, monoclonal antibodies and enzymes specifically designed for early diagnosis as well as therapeutic research. View our range of auto-immune bioreagents on our website.

Research scientists at ModiQuest Research have definitive expertise in autoimmune disease allowing them to provide deep insights drawn from their own extensive experience in the field, and an unrivalled suite of products and services specifically aimed at supporting autoimmune disease research. Examples of autoimmune products and services that ModiQuest Research provides include: an effective mix of anti-collagen monoclonal antibodies for generating collagen antibody-induced arthritis (CAIA) in mice; readily available ELISA assay kits for evaluating autoimmune-associated peptide de-imination; custom development of diagnostic assays for other autoimmune disease pathways, and bespoke arthritis preclinical mouse efficacy studies for analyzing the therapeutic effects of client compounds in rheumatoid arthritis mouse models.

“We have demonstrable success in generating anti-collagen antibody products for rheumatoid arthritis research and we have huge experience in the area of auto-immune and inflammatory disease” said Dr Jos Raats CEO of ModiQuest Research. “We are currently helping a number of companies potentiate autoimmune therapies and diagnostic kits by the application of our antibody products and expertise.”

ModiQuest Research, which was established in 2005, has extensive knowledge and experience of antibody technologies. With its state-of-the-art facilities, proprietary technology and end-to-end support services, ModiQuest Research is superbly placed to support the development and production of antibody-based therapies and diagnostics in the most efficient and cost effective way possible. If you are active in autoimmune research then Modiquest Research can help you maximize the potential of your project.

End

High resolution image attached or available from Claire England,
Kapler Communications claire@kapleronline.com Ref: MQR/JOB/006

About ModiQuest Research

ModiQuest Research has extensive knowledge and experience of antibody technologies. With state-of-the-art facilities and proprietary tools, ModiQuest Research supports the development and production of antibody-based therapies and diagnostics in the most efficient and cost effective way possible.

Established since 2005, ModiQuest Research is based in Nijmegen, The Netherlands, with a global customer base that includes small and large leading pharmaceutical and diagnostic companies as well as academic research teams.

ModiQuest B.V is a sister company that develops new antibody therapies and diagnostics for rheumatoid arthritis and inflammatory disorders.

For more information:

For press information, please contact:
Alexandra Jones, Kapler Communications
Knowledge Centre, Wyboston Lakes, Great North Road,
Wyboston, Bedfordshire, MK44 3BY, UK
Tel: +44 (0)1480 479280; Fax: +44 (0)1480 470343 alexandra@kapleronline.com

ModiQuest Research contact:
Dr. Jos Raats, ModiQuest Research B.V. Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
email: jraats@modiquestresearch.com

22 November 2011: ModiQuest Research, Nijmegen, The Netherlands: Jos Raats, CEO of ModiQuest has been invited to Bayer, Germany on 22 November to give a seminar on their novel, effective antibody-based treatments for Rheumatoid Arthritis.

The discoveries were made as a result of ModiQuest Research’s state-of-art proprietary technology platforms for efficient antibody generation, antibody cloning and reformatting, stable cell line development and antibody production facilities. These were used in combination with the company’s own highly effective rheumatoid arthritis mouse model, to identify and characterise promising antibody preclinical candidates. First and second generation mouse and human monoclonal antibodies have been identified and characterised as being able to slow or halt the onset and progression of arthritis in preclinical studies.

Together with early diagnostic testing which is already on the market, the discoveries by ModiQuest herald new possibilities for rheumatoid arthritis treatment that can be applied before the onset of clinical symptoms and irreversible joint damage. For established rheumatoid arthritis, the group demonstrated that these new antibodies have the potential to significantly decrease arthritis symptoms, in combination with current anti-inflammatory treatments.

For further information, contact Jos Raats, CEO ModiQuest, at jraats@modiquestresearch.com.

25 October 2011: ModiQuest Research, Nijmegen, The Netherlands: Combining accurate, early diagnostic tests for autoimmune disease, and new antibody treatment options are two themes being presented by antibody technology experts, ModiQuest Research at HAH 2011 (7-9 November 2011, Cannes, France). ModiQuest Research’s technology includes monoclonal antibody generation and specialist immunological reagents to support the research and development of new antibody therapies and diagnostics. President and CEO, Dr Jos Raats will present latest data on new antibodies and early diagnostics for rheumatoid arthritis, using their hybridoma and phage display platforms.

Dr Raats said, “The Human Antibodies and Hybridomas event will be a great opportunity to share knowledge with others in the field of antibody development. I am honoured to be delivering a paper entitled ‘Anti-Citrulline Antibody as Novel Therapeutic Drug in early Rheumatoid Arthritis,’ detailing ModiQuest Research’s development of a novel therapy for Rheumatoid Arthritis (RA). Using our antibody generation technologies, this new drug candidate was developed by focussing on targets like Deiminated Peptide-Epitopes (DPE), since a number of studies indicated that these deimination modifications could be responsible for the initial triggering of autoimmunity and the breaking of tolerance. We use the same technologies to support our clients in the development of new antibody therapies and diagnostics. ”

Modiquest Research are proud to be sponsors of Human Antibodies & Hybridomas 2011. This year the scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects of human antibody and hybridoma technology, applications and engineering. The scope of the conference falls broadly into eight main session categories; infectious diseases, autoimmunity, molecular biology, emerging technologies, clinical applications, therapeutic antibodies, cancer and anti-infective antibodies.

ModiQuest Research offers an intelligent approach to antibody generation, cloning and cell line production. Its offering includes monoclonal antibody generation, cell line services, plus antibody cloning and sequencing. Products available in the range include immunological reagents to enable early research into new antibody therapeutics and diagnostics. These products contain unique and highly specialised reagents to enable research in autoimmune disease, infectious diseases including fungal and parasitic diseases and oncology and are available to purchase online via ModiQuest’s website.

For more information about ModiQuest and to see Dr Raats in action, please click on http://bit.ly/MQR003video or visit www.modiquestresearch.com

End

High resolution image attached or available from Claire England,
Kapler Communications claire@kapleronline.com Ref: MQR/JOB/005a

About ModiQuest Research

ModiQuest Research has extensive knowledge and experience of antibody technologies. With state-of-the-art facilities and proprietary tools, ModiQuest Research supports the development and production of antibody-based therapies and diagnostics in the most efficient and cost effective way possible.

Established since 2004, ModiQuest Research is based in Nijmegen, The Netherlands, with a global customer base that includes small and large leading pharmaceutical and diagnostic companies as well as academic research teams.

ModiQuest B.V is a sister company that develops new antibody therapies and diagnostics for rheumatoid arthritis and inflammatory disorders.

For more information:

For press information, please contact:
Alexandra Jones, Kapler Communications
Knowledge Centre, Wyboston Lakes, Great North Road,
Wyboston, Bedfordshire, MK44 3BY, UK
Tel: +44 (0)1480 479280; Fax: +44 (0)1480 470343 alexandra@kapleronline.com

ModiQuest Research contact:
Dr. Jos Raats, ModiQuest Research B.V. Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
email: jraats@modiquestresearch.com

07 October 2011: ModiQuest Research, Nijmegen, The Netherlands: Rapid growth in the monoclonal antibodies market has been made possible by technological advances in recombinant monoclonal technologies, showcased by antibody technology experts, ModiQuest Research, at BIOTECHNICA 2011 (11-13 October, Hannover, Germany). ModiQuest CEO and President, Dr Jos Raats will be on hand to discuss how their technologies and specialist reagents have enabled research and development of new antibody treatments, plus diagnostics, across a range of therapy areas including autoimmune disease and cancer.

Dr Raats said, “We’re looking forward to meeting researchers in antibody treatments and diagnostics. It is always mutually beneficial to share knowledge gained with others working in the field of antibody development. At ModiQuest we develop antibody-related solutions for even the most intractable targets, so we have a great deal of experience solving the challenges of this growing area of drug development. There is also a great deal of interest in our suite of specialist services and products to support rheumatoid arthritis and other immune disease related research.”

Dr Raats will be on hand to discuss today’s challenges of antibody development and production at ModiQuest’s exhibition booth as part of the Netherlands Pavilion in Hall 9, Stand G04. BIOTECHNICA 2011 is an event which traditionally has four core areas – biotechnology, lab technology, services and technology transfer. This year major trends for the future with be examined with three focus themes: BioServices, Biotechnological Innovation in Food and Industrial Biotechnology.

ModiQuest Research offers an intelligent approach to antibody generation, cloning, modification and cell line production. Its offering includes end-to-end support services that include monoclonal antibody generation, cell line development and antibody production, plus antibody cloning and sequencing to enable academic, pharmaceutical and biotechnology clients to develop new and improved antibody treatments and diagnostics. In addition ModiQuest Research provides a range of immunological reagents to enable early research into treatments for autoimmune, cancer and infectious diseases.

Click on the ModiQuest Corporate Video for an introduction to the company or visit the company website here.

End

High resolution image attached or available from Claire England,
Kapler Communications claire@kapleronline.com Ref: MQR/JOB/003a

About ModiQuest Research

ModiQuest Research has extensive knowledge and experience of antibody technologies. With state-of-the-art facilities and proprietary tools, ModiQuest Research supports the development and production of antibody-based therapies and diagnostics in the most efficient and cost effective way possible.
Established since 2004, ModiQuest Research is based in Nijmegen, The Netherlands, with a global customer base that includes small and large leading pharmaceutical and diagnostic companies as well as academic research teams.

ModiQuest B.V is a sister company that develops new antibody therapies and diagnostics for rheumatoid arthritis and inflammatory disorders.

For more information:

For press information, please contact:
Alexandra Jones, Kapler Communications
Knowledge Centre, Wyboston Lakes, Great North Road,
Wyboston, Bedfordshire, MK44 3BY, UK
Tel: +44 (0)1480 479280; Fax: +44 (0)1480 470343 alexandra@kapleronline.com

ModiQuest Research contact:
Dr. Jos Raats, ModiQuest Research B.V. Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
email: jraats@modiquestresearch.com

ModiQuest Research, Nijmegen, The Netherlands: ModiQuest Research, the antibody technology experts, announce the launch of their new website (www.modiquestresearch.com). With a fresh new look, it will save time and effort for antibody research teams worldwide. An intuitive structure, ‘quick quotes’ and fixed pricing look set to make www.modiquestresearch.com the go-to resource for the routine purchase of a wide range of antibody products and services.

With customers from new start-ups to large, multi-national organisations, ModiQuest Research takes an intelligent approach to antibody design, modification, cloning and production. The company is proud of its reputation for high-quality products. Proprietary tools and know-how that extends across the field of antibody research characterise the ModiQuest Research team. Areas of activity include: monoclonal antibody generation, antibody cloning and sequencing, stable and transient cell line services, antibody production, and antibody modification services.

A young and dynamic company, ModiQuest Research focuses on high-throughput generation of monoclonal human- and animal-derived antibodies. Antibodies are generated from both human and animal origin, using a large panel of state-of-the-art technologies, such as ModiQuest Research’s proprietary hybridoma generation, B-cell selection and phage display. Their growing range of immunological research products include specialist reagents for autoimmune diseases, infectious diseases and cancer.

End

High resolution image attached or available from Claire England,
Kapler Communications claire@kapleronline.com Ref: MQR/JOB/002

About ModiQuest Research

ModiQuest Research has extensive knowledge and experience of antibody technologies. With state-of-the-art facilities and proprietary tools, ModiQuest Research supports the development and production of antibody-based therapies and diagnostics in the most efficient and cost effective way possible.
Established since 2004, ModiQuest Research is based in Nijmegen, The Netherlands, with a global customer base that includes small and large leading pharmaceutical and diagnostic companies as well as academic research teams.

ModiQuest B.V is a sister company that develops new antibody therapies and diagnostics for rheumatoid arthritis and inflammatory disorders.

For more information:

For press information, please contact:
Alexandra Jones, Kapler Communications
Knowledge Centre, Wyboston Lakes, Great North Road,
Wyboston, Bedfordshire, MK44 3BY, UK
Tel: +44 (0)1480 479280; Fax: +44 (0)1480 470343 alexandra@kapleronline.com

ModiQuest Research contact:
Dr. Jos Raats, ModiQuest Research B.V. Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
email: jraats@modiquestresearch.com